2019-11-14T13:49:36-06:00 2018-12-31 BDO USA LLP 8401 GREENSBORO DRIVE 800 MCLEAN VA 22102 990 2018-01-01 136180380 AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC % LINDA JENSEN CFO AMER 5714831300 2318 MILL ROAD Suite 800 ALEXANDRIA VA 22314 LINDA JENSEN CFO 5714831300 2019-11-14 true Marc Berger P01871563 7038930600 4.35.255.34 54621820193185000044 2019-11-14 P C44969C09172B32DC5279494C6AE8494327A5917 F80C4C4CE64063363A32333BB37C43EAD2BBFD59 2018 2020-04-17 16:48:07Z CLIFFORD HUDIS MD CEO 2318 MILL ROAD 800 ALEXANDRIA VA 22314 280186634 false X WWW.ASCO.ORG X 1964 NY ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, PREVENTION AND DELIVERY OF HIGH QUALITY PATIENT CARE. 17 17 552 2981 19293789 5515886 9978694 8575801 111649833 136574903 20138405 11398200 2771589 3335190 144538521 159884094 3197652 1168748 0 0 54588773 59231331 0 0 3398108 78774427 85406395 136560852 145806474 7977669 14077620 228266590 227652015 117378146 118594943 110888444 109057072 X SEE SCHEDULE O false false 41485198 23816342 QUALITY OF CARE:SEE SCHEDULE O 40810563 414420 68809113 SCIENTIFIC AND MEDICAL EDUCATION: SEE SCHEDULE O 14987108 64000 30338860 SCIENTIFIC PUBLICATIONS: SEE SCHEDULE O 35520575 690327 13610589 132803444 true true false true false false false false false false true false false false true true false true false true true true true false false false false true false true true false false false false false false false false false false false false false false true true true true false false true 454 0 true 552 true true true false false false false false false false false false false false X 17 17 false false false false true true true true true true false true true true true true true true true false CA NY VA X LINDA JENSEN CFO 5714831300 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 Bruce Johnson MD PAST President 1.0 0.0 X X 0 0 0 Monica Bertagnolli MD President 1.0 0.0 X X 0 0 0 Peter Adamson MD Board Member 1.0 0.0 X 0 0 0 Stephen B Edge MD Board Member 1.0 0.0 X 0 0 0 Arti Hurria MD Board Member 1.0 0.0 X 500 0 0 Maha HussainMD Board Member 1.0 0.0 X 0 0 0 J Chris Nunnink MD Board Member 1.0 0.0 X 0 0 0 Reshma Jagsi MD Dphil Board Member 1.0 0.0 X 0 0 0 Michael KostyMD Board Member 1.0 0.0 X 1250 0 0 Eric Small MD Board Member 1.0 0.0 X 0 0 0 Jedd Wolchok MD Board Member 1.0 0.0 X 0 0 0 HOWARD A BURRIS III MD PRESIDENT-ELECT 1.0 0.0 X X 0 0 0 LAURIE GASPAR MDMBA TREASURER 1.0 0.0 X X 0 0 0 A WILLIAM BLACKSTOCK MD BOARD MEMBER 1.0 0.0 X 0 0 0 LEE ELLIS MD FACS BOARD MEMBER 0.0 0.0 X 0 0 0 TONY SHU KAM MOK MD BOARD MEMBER 1.0 0.0 X 0 0 0 JAAP VERWEIJ MD PHD BOARD MEMBER 1.0 0.0 X 0 0 0 TRACEY WEISBERG MD BOARD MEMBER 1.0 0.0 X 0 0 0 CRAIG NICHOLS MD FACP TREASURER - PARTIAL YEAR 1.0 0.0 X 0 0 0 DANIEL HAYES MD PAST PRESIDENT - PARTIAL YEAR 1.0 0.0 X 0 0 0 CHARLES BLANKE MD BOARD MEMBER 1.0 0.0 X 0 0 0 LINDA BOSSERMAN MD BOARD MEMBER 1.0 0.0 X 0 0 0 WALTER CURRAN JR MD BOARD MEMBER 1.0 0.0 X 0 0 0 DAVID KHAYAT MD PHD BOARD MEMBER 1.0 0.0 X 7500 0 0 Clifford HudisMD CEO, NON-VOTING DIRECTOR 30.0 7.5 X 864309 0 24173 Dina Michels Esq Senior VP, CHIEF LEGAL OFFICER 30.0 7.5 X 564263 0 38168 Linda Jensen CPA Chief Financial Officer 30.0 7.5 X 414231 0 38168 Richard Schilsky MD Chief Medical Officer 30.0 7.5 X 584423 0 37388 Nancy Daly MS MPH Executive DIRECTOR 1.0 36.5 X 369808 0 38168 Kevin Fitzpatrick CancerLinQ CEO 37.5 0.0 X 429905 0 19412 Jamie Von Roenn MD VP, Education 37.5 0.0 X 377615 0 38168 Bernie Khoo VP, Integrated Media 35.0 2.5 X 417615 0 39969 Deborah Kamin RN PHD VP, POLICY AND ADVOCACY 37.5 0.0 X 294615 0 37904 Krista Barnes VP, Member Services 30.0 7.5 X 228015 0 37876 Amanda Davis-Aitken VP, MeetingS 30.0 7.5 X 194615 0 22573 CORY WIEGERT CANCERLINQ CEO 30.0 7.5 X 189462 0 5848 DAVID SAMPSON VICE PRESIDENT PUBLICATIONS 37.5 0.0 X 239615 0 40357 Stephen Grubbs MD VP, Clinical Affairs 37.5 0.0 X 377615 0 37388 Robert Miller MD CANCERLINQ MEDICAL DIRECTOR 37.5 0.0 X 352808 0 43386 Kristin Ludwig VP, Communications 37.5 0.0 X 270769 0 23481 CARMEN JACKSON CANCERLINQ CHIEF OF OPERATIONS 37.5 0.0 X 273500 0 43199 ANIL NAIR CANCERLINQ CHIEF TECH OFFICER 37.5 0.0 X 244420 0 40487 6696853 0 606113 177 false true false SAP PUBLIC SERVICES INC PO BOX 828795 PHILADELPHIA PA 19182 TECHNOLOGY SERVICES 3129508 SPARGO INC 11208 Waples Mill Rd FAIRFAX VA 22030 EVENT PLANNING 2344984 SHERIDAN PRESS 450 FAME AVENUE HANOVER PA 17331 PRINTING SERVICES 1959417 KAMIS PROFESSIONAL STAFFING 9841 WASHINGTON BLVD STE 200 GAITHERSBURG MD 20878 STAFFING SERVICES 1281049 WALCHLI TAUBER GROUP INC 2225 OLD EMMORTON RD STE 201 BEL AIR MD 21015 ADVERTISING SERVICES 1237136 65 8575801 8575801 DUES 900099 7029816 7029816 EDUCATIONAL MEETINGS & PRODUCTS 900099 68809112 65132922 3676190 EDUCATIONAL PUBLICATIONS 511190 30338860 16406007 13932853 QUALITY 900099 23816342 23190362 625980 MEMBER RELATIONS & INFORMATION 900099 343906 42377 301529 6236867 6236867 136574903 5440434 5440434 0 2322608 2322608 1159810 462631 697179 0 697179 697179 125797675 119839909 5957766 5957766 5957766 0 0 0 0 0 0 0 0 0 MAILING LIST 255345 255345 TENANT PARKING INCOME 60058 60058 315403 159884094 118038351 19293789 13976153 X 980436 980436 0 0 188312 188312 0 7295466 4521435 2549644 224387 0 41042081 39369893 1672188 2665450 2494303 171147 4922410 4517759 404651 3305924 3003327 302597 0 603867 557974 45893 152533 150723 1810 182658 182658 0 85322 85322 28176513 27192348 984165 0 494151 471397 22754 2699444 2406588 292721 135 10082028 9128209 953819 0 3327984 3287788 40196 6943382 6894535 44702 4145 0 12267669 12137724 75376 54569 3287423 2386668 900755 0 3379081 2471172 907909 693927 561169 132758 PRINTING & PRODUCTION 4715834 4708484 6806 544 DEVELOPMENT FEE TO RELATED ORG 3114004 3114004 UBI TAX 1768861 1767745 1116 0 POSTAGE & SHIPPING 1321045 1316524 4197 324 2110669 2106273 4396 145806474 132803444 9604922 3398108 0 0 8382288 10106685 0 0 7615148 16453791 0 0 0 0 0 0 0 0 4792902 7481194 75723838 26673595 50169634 49050243 132611260 142567125 24593902 1992977 0 0 0 0 101456 0 228266590 227652015 9930921 17199923 0 0 33691508 31345157 38400000 38400000 0 0 0 0 0 0 0 0 35355717 31649863 117378146 118594943 X 110888444 109057072 0 0 0 0 110888444 109057072 228266590 227652015 X 14077620 -18496900 2587908 X false true X true false X 9775055 13960857 11941446 9978694 8575801 54231853 83008682 88958786 78719498 93297144 136574903 480559013 0 0 0 92783737 102919643 90660944 103275838 145150704 534790866 12876427 13914277 11641675 9856323 8575801 56864503 0 12876427 13914277 11641675 9856323 8575801 56864503 477926363 5821197 6401944 5651063 5969247 7763043 31606494 0 5821197 6401944 5651063 5969247 7763043 31606494 3584676 3133751 3414649 2871782 4855029 17859887 306781 277776 248859 255345 1088761 102189610 112762119 100004432 112365726 158024121 585346008 0.81649 0.79617 0.05400 0.05602 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1947 198306 200253 132603191 132803444 1000000 250000 1000000 1000000 1000000 1000000 4000000 6000000 212384 259559 291378 198306 961627 250000 250000 250000 250000 1000000 1500000 8424 3346 2905 0 14675 7342677 7342677 46941779 12291361 34650418 773776 379184 394592 5682239 4147662 1534578 14983365 9855387 5127978 49050243 0 LIABILITY UNDER INTEREST RATE SWAP 10361419 TAXABLE BOND PAYABLE 17962330 DUE TO RELATED ORGANIZATION 3326114 31649863 X 144352411 -18496900 2587908 -15908992 160261403 85322 -462631 -377309 159884094 146183783 462631 462631 145721152 85322 85322 145806474 PART X, LINE 2 IN ACCORDANCE WITH GAAP, THE ORGANIZATION MAY RECOGNIZE THE TAX BENEFIT FROM AN UNCERTAIN TAX POSITION ONLY IF IT IS MORE LIKELY THAN NOT THAT THE TAX POSITION WILL BE SUSTAINED ON EXAMINATION BY TAXING AUTHORITIES, BASED ON TECHNICAL MERITS OF THE POSITION. THE TAX BENEFITS RECOGNIZED IN THE CONSOLIDATED FINANCIAL STATEMENTS FROM SUCH A POSITION ARE MEASURED BASED ON THE LARGEST BENEFIT THAT HAS A GREATER THAN 50% LIKELIHOOD OF BEING REALIZED UPON ULTIMATE SETTLEMENT. THE ORGANIZATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR TAX POSITIONS TAKEN, AND THEREFORE, DOES NOT HAVE UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE CONSOLIDATED FINANCIAL STATEMENTS. GENERALLY, THE ORGANIZATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS PRIOR TO DECEMBER 31, 2015. PART XI, LINE 2D GAIN ON INTEREST RATE SWAP $2,587,908 PART XI, LINE 4B RENTAL EXPENSES -$462,631 PART XII, LINE 2D RENTAL EXPENSES $462,631 true East Asia and the Pacific Program Services OUTREACH & EDUCATIONAL 222547 South America Program Services OUTREACH & EDUCATIONAL 55896 Central America and the Caribbean Program Services OUTREACH & EDUCATIONAL 41468 Europe (Including Iceland and Greenland) Program Services OUTREACH & EDUCATIONAL 112564 North America Program Services OUTREACH & EDUCATIONAL 84142 Russia and the Newly Independent States Program Services OUTREACH & EDUCATIONAL 62694 South Asia Program Services OUTREACH & EDUCATIONAL 439796 Sub-Saharan Africa Program Services OUTREACH & EDUCATIONAL 383797 Central America and the Caribbean Investments 1806846 3209750 3209750 Europe (Including Iceland and Greenland) contribution 94217 check Europe (Including Iceland and Greenland) contribution 12855 check Europe (Including Iceland and Greenland) CONTRIBUTION 10000 wire 2 1 idea award East Asia and the Pacific 3 3620 cash/check 7681 Travel Book idea award Europe (Including Iceland and Greenland) 2 2360 cash/check 3356 travel book idea award North America 2 2200 cash/check 2073 travel book idea award South America 1 1100 cash/check 1738 travel book idea award South Asia 7 8500 cash/check 13833 travel book idea award Sub-Saharan Africa 6 7225 cash/check 12264 travel book idea award Central America and the Caribbean 1 1100 cash/check 1006 travel book idea award Russia and the Newly Independent States 1 1260 cash/check 1924 travel book true false false false false true SCHEDULE F, PART I, LINE 1 INTERNATIONAL DEVELOPMENT AND EDUCATION AWARDS (IDEA) - THE INTERNATIONAL DEVELOPMENT AND EDUCATION AWARDS PROVIDE SUPPORT FOR EARLY-CAREER ONCOLOGISTS IN DEVELOPING COUNTRIES TO LEARN ABOUT ONCOLOGY CARE AND RESEARCH BY ESTABLISHING STRONG RELATIONSHIPS WITH LEADING ASCO ONCOLOGISTS WHO SERVE AS SCIENTIFIC MENTORS TO EACH RECIPIENT. RECIPIENTS LEARN ABOUT QUALITY CANCER CARE AND RESEARCH BY ATTENDING THE ASCO ANNUAL MEETING AND VISITING THEIR MENTOR'S CANCER CENTER IN THE UNITED STATES AND CANADA. RECIPIENTS ARE EXPECTED TO SHARE THE KNOWLEDGE AND TRAINING THEY RECEIVE THROUGH THE PROGRAM WITH COLLEAGUES IN THEIR HOME COUNTRIES ONCE THEY RETURN. IDEAS ARE PROVIDED TO RECIPIENTS BASED ON MERIT THROUGH A PEER REVIEW PROCESS USING ESTABLISHED ELIGIBILITY CRITERIA. IDEA RECIPIENTS ARE REQUIRED TO AGREE TO TERMS AND CONDITIONS APPLICABLE TO THE IDEA, ARE REQUIRED TO COMMUNICATE WITH THEIR MENTORS, TO ATTEND ALL IDEA-RELATED EVENTS, TO SUBMIT EVALUATIONS AFTER THE ANNUAL MEETING AND MENTOR SITE VISIT, AND TO SUBMIT ONE-YEAR REPORTS. true Conquer Cancer Foundation of ASCO 2318 Mill Rd Ste 800 Alexandria VA 22314 311667995 501(c)(3) 3503004 Contribution Regents of the University of Michigan 300 N Ingalls St Ann Arbor MI 48109 386006309 501(c)(3) 25000 Contribution Dana Farber Cancer Institute 450 Brookline Ave Boston MA 02215 042263040 501(c)(3) 126667 Contribution Friends of Cancer Research 3299 K Street NW Washington DC 20007 521983273 501(c)(3) 35000 Contribution National Academy of Sciences 2101 Constitution Ave Washington DC 20418 530196932 501(c)(3) 16500 Contribution Duke University Medical Center 2424 Erwin Rd Suite 601 Durham NC 27705 560532129 501(c)(3) 25000 Contribution National Coalition for Cancer Survivorship 1010 Wayne Ave 770 Silver Spring MD 20910 850357897 501(c)(3) 10000 Contribution Health Volunteers Overseas 1900 L St NW 310 washington DC 20036 521485477 501(C)(3) 10000 contribution WETA 3939 Campbell Avenue Arlington VA 22206 530242992 501(c)(3) 75000 Contribution Brigham & Women's Hospital 75 Francis St T 1 Rm 220 Boston MA 02215 042312909 501(c)(3) 161667 Contribution Susan G Komen Foundation 5005 LBJ Freeway Ste 250 Dallas TX 75244 751835298 501(c)(3) 25000 Contribution SARAH CANNON RESEARCH INSTITUTE ONE PARK PLAZA NASHVILLE FL 32703 201557751 46667 CONTRIBUTION BANNER HEALTH 2901 N CENTRAL AVE STE 160 PHOENIX AZ 85012 450233470 501(c)(3) 35000 CONTRIBUTION AMERICAN CHILDHOOD CANCER ORGANIZATION PO BOX 498 KENSINGTON MD 20705 521071826 501(c)(3) 7000 CONTRIBUTION 13 1 SCHEDULE I, PART I, LINE 1 ASCO provides assistance to 501(c)(3) organizations that serve the cancer community. SCHEDULE I, PART I, LINE 2 ASCO PROVIDES ASSISTANCE TO ORGANIZATIONS THAT SERVE THE CANCER CARE COMMUNITY. THE MAJORITY OF THESE GRANTS ARE MADE TO OTHER 501(C)(3) ORGANIZATIONS. THE GRANT MADE TO A NON-501(C)(3) ORGANIZATION WAS MADE PURSUANT TO A WRITTEN AGREEMENT THAT REQUIRED THE GRANT FUNDS TO BE USED FOR SPECIFIC EDUCATIONAL AND CHARITABLE PROJECTS, THAT THE GRANTEE RETURN ANY PORTION OF THE GRANT FUNDS THAT WERE NOT USED FOR SUCH PROJECTS, AND THAT THE GRANTEE PROVIDE ANNUAL NARRATIVE AND FINANCIAL REPORTS TO ASCO REGARDING GRANTEE'S USE OF THE GRANT FUNDS. X X X X X X true false false false false false false true false Clifford HudisMD CEO, NON-VOTING DIRECTOR 794784 0 69525 0 0 0 20625 0 3548 0 888482 0 0 0 Richard Schilsky MD Chief Medical Officer 554423 0 30000 0 0 0 20625 0 16763 0 621811 0 0 0 Dina Michels Esq Senior VP, CHIEF LEGAL OFFICER 554263 0 10000 0 0 0 20625 0 17543 0 602431 0 0 0 Linda Jensen CPA Chief Financial Officer 379231 0 35000 0 0 0 20625 0 17543 0 452399 0 0 0 Nancy Daly MS MPH Executive DIRECTOR 364808 0 5000 0 0 0 20625 0 17543 0 407976 0 0 0 Kevin Fitzpatrick CancerLinQ CEO 348308 0 65000 0 16597 0 10630 0 8782 0 449317 0 0 0 Jamie Von Roenn MD VP, Education 369615 0 8000 0 0 20625 0 17543 0 415783 0 0 0 Bernie Khoo VP, Integrated Media 409615 0 8000 0 0 0 20625 0 19344 0 457584 0 0 0 Stephen Grubbs MD VP, Clinical Affairs 369615 0 8000 0 0 0 20625 0 16763 0 415003 0 0 0 Robert Miller MD CANCERLINQ MEDICAL DIRECTOR 349808 0 3000 0 0 0 20625 0 22761 0 396194 0 0 0 Deborah Kamin RN PHD VP, POLICY AND ADVOCACY 286615 0 8000 0 0 0 20625 0 17279 0 332519 0 0 0 Kristin Ludwig VP, Communications 265769 0 5000 0 0 0 19933 0 3548 0 294250 0 0 0 Krista Barnes VP, Member Services 219615 0 7500 0 900 0 16471 0 21405 0 265891 0 0 0 Amanda Davis-Aitken VP, MeetingS 189615 0 5000 0 0 0 14221 0 8352 0 217188 0 0 0 CORY WIEGERT CANCERLINQ CEO 138462 0 51000 0 0 0 5848 0 0 0 195310 0 0 0 CARMEN JACKSON CANCERLINQ CHIEF OF OPERATIONS 273500 0 0 0 0 0 20438 0 22761 0 316699 0 0 0 ANIL NAIR CANCERLINQ CHIEF TECH OFFICER 244420 0 0 0 0 0 19082 0 21405 0 284907 0 0 0 DAVID SAMPSON VICE PRESIDENT PUBLICATIONS 234615 0 5000 0 0 0 17596 0 22761 0 279972 0 0 0 Part I, Line 4a: KEVIN FITZPATRICK RECEIVED SEVERANCE IN THE AMOUNT OF $16,597 DURING 2018 WHICH IS LISTED IN SCHEDULE J, PART II, COLUMN (B)(III). Part I, Line 7: PERFORMANCE-BASED BONUS PAYMENTS CAN BE MADE TO SOME EMPLOYEES LISTED ON SCHEDULE J AND INCLUDED AS PART OF THE TOTAL COMPENSATION. THE BONUS PAYMENTS ARE NOT ON A FIXED BASIS BUT RATHER ARE BASED ON PERFORMANCE AND DETERMINED BY THE CEO WITH REVIEW AND APPROVAL BY THE COMPENSATION COMMITTEE OF THE BOARD, WHERE APPROPRIATE. A INDUSTRIAL DEVELOPMENT AUTHORITYCITY OF ALEXANDRI 521381432 01530lad2 2012-08-01 38400000 Buy/Buildout 5 floors HQ building false false false A 0 0 38400000 0 0 0 0 0 0 38400000 0 0 2008 true false true true A false false true true false 0 0.00089 0.00089 false false false true A false true true false true true fms wentworth 30. false false false 0 true A true PART IV, QUESTION 3 ASCO HAS AN INTEREST RATE SWAP AGREEMENT WITH FMS WENTWORTH BANK THROUGH 2038. ASCO MAKES FIXED INTEREST PAYMENTS AT A 3.587% RATE. VARIABLE SWAP PAYMENTS, BASED ON ONE-MONTH LIBOR, RECEIVED FROM THE SWAP COUNTERPARTY ARE USED TO MAKE THE VARIABLE INTEREST PAYMENTS AS THEY COME DUE. THIS INTEREST RATE SWAP AGREEMENT QUALIFIES AS A DERIVATIVE INSTRUMENT AND IS USED TO MITIGATE THE EFFECT OF INTEREST RATE FLUCTUATIONS. FORM 990, PART III, LINE 1 ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY PATIENT CARE. ASCO'S VISION IS A WORLD WHERE CANCER IS PREVENTED OR CURED, AND EVERY SURVIVOR IS HEALTHY. ASCO PROMOTES AND PROVIDES FOR: - CANCER RESEARCH, - AN IMPROVED ENVIRONMENT FOR ONCOLOGY PRACTICE, - ACCESS TO QUALITY CANCER CARE, - A GLOBAL NETWORK OF ONCOLOGY EXPERTISE, AND - EDUCATED AND INFORMED PATIENTS WITH CANCER. FORM 990, PART III, LINE 4A QUALITY OF CARE: ASCO PRODUCES EVIDENCE-BASED GUIDELINES, DEVELOPS AND VALIDATES QUALITY MEASURES IN ONCOLOGY, AND CONDUCTS QUALITY MEASUREMENT AND IMPROVEMENT ACTIVITIES PROGRAMS INCLUDE: -CANCERLINQ. THIS BIG-DATA BASED, RAPID LEARNING SYSTEM IN ONCOLOGY HAS BEEN DEVELOPED, BY ASCO'S WHOLLY-OWNED SUBSIDIARY, CANCERLINQ LLL, TO VASTLY IMPROVE THE WAY ONCOLOGISTS PRACTICE, LEARN, AND DETERMINE THE BEST TREATMENT OPTIONS FOR THEIR PATIENTS. -QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES. QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICE STAFF TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. - CLINICAL PRACTICE GUIDELINES AND UPDATES. ASCO HAS PUBLISHED MORE THAN 50 PRACTICE GUIDELINES, ENDORSEMENTS, AND PROVISIONAL CLINICAL OPINIONS (PCO'S) ADDRESSING A WIDE RANGE OF CANCER TREATMENT, DIAGNOSIS, AND MANAGEMENT ISSUES. - QOPI REPORTING REGISTRY. ASCO PROVIDES A QUALIFIED CLINICAL DATA REGISTRY TO HELP MEMBERS SATISFY THE FEDERAL GOVERNMENTS MERIT-BASED INCENTIVE PAYMENT SYSTEM (MIPS) REPORTING REQUIREMENTS. - QUALITY TRAINING PROGRAM. ASCOS QUALITY TRAINING PROGRAM IS DESIGNED TO HELP PRACTICES IMPROVE CLINICAL CARE AND OPERATIONAL PERFORMANCE. IN ADDITION, ASCO OFFERS PRACTICE MANAGEMENT PROGRAMS AND PRODUCTS DESIGNED TO SUPPORT PRACTICE HEALTH TO ENABLE PRACTICES TO DELIVER HIGH QUALITY CARE. THESE RESOURCES INCLUDE: - PRACTICENET. THIS LEARNING NETWORK IS FOCUSED ON HELPING PRACTICES IMPROVE THEIR BUSINESS OPERATIONS - FDA ALERTS. ASCO PARTNERS WITH THE FDA TO PROVIDE ITS MEMBERS TIMELY SAFETY ALERTS AND NOTICES OF NEWLY APPROVED CANCER THERAPIES. FORM 990, PART III, LINE 4B SCIENTIFIC AND MEDICAL EDUCATION: ASCO PROVIDES SCIENTIFIC AND EDUCATIONAL PROGRAMS AND CONTENT ON A BROAD RANGE OF ONCOLOGY-RELATED TOPICS IN A VARIETY OF FORMATS. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS AND PRESENTS LIVE MEETINGS ON THE LATEST RESEARCH AND ADVANCES IN THE FIELD OF CLINICAL ONCOLOGY. THE ONCOLOGY-SPECIFIC INFORMATION PRESENTED AT THESE MEETINGS ENHANCES KNOWLEDGE ABOUT TREATING CANCER AND CARING FOR CANCER PATIENTS. THE ASCO ANNUAL MEETING IS THE WORLD'S PREMIER SCIENTIFIC AND EDUCATIONAL MEETING IN THE ONCOLOGY COMMUNITY. THE THEMATIC MEETINGS, PRESENTED OR CO-SPONSORED BY ASCO, PROVIDE OPPORTUNITIES FOR FOCUSED EDUCATIONAL AND SCIENTIFIC SESSIONS ON SPECIFIC TYPES OF CANCERS. ASCO'S PROGRAMS ARE DESIGNED TO SERVE THE DIVERSE NEEDS OF ONCOLOGY PRACTITIONERS WORLDWIDE TO ASSIST THEM IN DELIVERING HIGH QUALITY CANCER CARE AND CONDUCTING CLINICAL RESEARCH THROUGH THE CONTINUUM OF THEIR CAREERS. PROGRAMS ADDRESS THE MODERN-DAY PRACTICE OF ONCOLOGY FOR ALL LEVELS OF PRACTITIONERS INCLUDING ONCOLOGY FELLOWS, JUNIOR FACULTY MEMBERS, ONCOLOGY PROGRAM DIRECTORS, ETC. ASCO'S EDUCATIONAL PROGRAMS INCLUDE PLANNING, IMPLEMENTATION AND EVALUATION OF CONTINUING MEDICAL EDUCATION (CME) TO SUPPORT THE CONTINUED EDUCATION OF ONCOLOGISTS AND OTHER MEMBERS OF THE CANCER CARE TEAM TO ENABLE THEM TO BETTER MEET THE PREVENTION, DIAGNOSIS AND TREATMENT NEEDS OF THEIR PATIENTS. CURRENTLY, ASCO HOLDS THE STATUS OF ACCREDITATION WITH COMMENDATION FROM THE ACCREDITATION COUNCIL FOR CME FOR ASCO'S CME PROGRAM. ASCO MAKES MUCH OF THE CONTENT FROM ITS MEETINGS AND OTHER EDUCATIONAL AND SCIENTIFIC CONTENT PUBLICLY AVAILABLE THROUGH TWO ASCO WEBSITES: WWW.ASCO.ORG AND WWW.CANCER.NET. ADDITIONALLY, ASCO MAKES SCIENTIFIC AND EDUCATIONAL MATERIALS AVAILABLE THROUGH A VARIETY OF CHANNELS, INCLUDING BOOKS, DVDS, VIRTUAL MEETINGS, PODCASTS AND PUBLIC FORUMS. HIGHLIGHTS OF THE 2018 ACTIVITIES INCLUDE: OVER 40,000 PEOPLE ATTENDED THE 2018 ASCO ANNUAL MEETING, INCLUDING PHYSICIANS, NURSES, CAREGIVERS, PATIENTS, AND PATIENT ADVOCATES. APPROXIMATELY 40% OF THE ATTENDEES AT THE 2018 ASCO ANNUAL MEETING WERE INTERNATIONAL ATTENDEES. THE 2018 ANNUAL MEETING FEATURED OVER 265 EDUCATIONAL AND SCIENTIFIC SESSIONS AND OVER 5,000 ABSTRACTS WERE PRESENTED OR PUBLISHED. NEARLY 5,000 PRESENTATIONS WERE CAPTURED IN AUDIO AND VIDEO TO BE MADE AVAILABLE ELECTRONICALLY. IN ADDITION TO THE ASCO ANNUAL MEETING, ASCO SPONSORS OR CO-SPONSORS MORE THAN 40 EDUCATIONAL AND SCIENTIFIC SYMPOSIA, WORKSHOPS, AND COURSES INSIDE AND OUTSIDE THE UNITED STATES ON A WIDE VARIETY OF CANCER-RELATED TOPICS TO IMPROVE ONCOLOGY CARE WORLDWIDE. THESE MEETINGS INCLUDE: - BEST OF ASCO - PALLIATIVE AND SUPPORTIVE CARE IN ONCOLOGY SYMPOSIUM - QUALITY CARE SYMPOSIUM - GASTROINTESTINAL CANCERS SYMPOSIUM - GENITOURINARY CANCERS SYMPOSIUM - CANCER SURVIVORSHIP SYMPOSIUM - CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM INTERNATIONAL AFFAIRS MEETINGS AND COURSES: - BEST OF ASCO INTERNATIONAL - JOINT SYMPOSIA - ADVANCED CANCER COURSES - MULTIDISCIPLINARY CANCER MANAGEMENT COURSES ASCO PUBLISHES DAILY NEWS PRODUCTS FOR EACH OF ITS MAJOR MEETINGS. THESE PRODUCTS INCLUDE PRINT NEWSPAPERS THAT ARE DISTRIBUTED ONSITE TO ALL ATTENDEES AND PUBLICLY AVAILABLE ONLINE. THE DAILY NEWS PRODUCTS PROVIDE EDITORIAL COVERAGE OF KEY MEETING SESSIONS, COMMENTARIES BY EXPERTS IN VARIOUS SUBSPECIALTIES, INFORMATION ABOUT ASCO PRODUCTS AND RESOURCES, PROFILES OF GRANT AND AWARD WINNERS, AND OTHER TOPICS OF INTEREST TO ASCO MEMBERS AND MEETING ATTENDEES FROM AROUND THE WORLD. FORM 990, PART III, LINE 4C SCIENTIFIC PUBLICATIONS: ASCO PRODUCES A NUMBER OF PROFESSIONAL PUBLICATIONS FOCUSED ON CLINICAL ONCOLOGY. - ASCO PUBLISHES SEVERAL PEER-REVIEWED SCIENTIFIC JOURNALS - JOURNAL OF CLINICAL ONCOLOGY (JCO) IS A HIGHLY REGARDED, PEER-REVIEWED JOURNAL THAT DISSEMINATES QUALITY ARTICLES ON SIGNIFICANT CLINICAL ONCOLOGY RESEARCH IN PRINT AND ELECTRONIC FORMATS. - JOURNAL OF ONCOLOGY PRACTICE (JOP) INCLUDES ORIGINAL RESEARCH AND PERSPECTIVES ON CLINICAL AND ADMINISTRATIVE MANAGEMENT ADDRESSING THE PRACTICE OF ONCOLOGY, WHICH ARE EDITED BY ONCOLOGISTS. - THE JOURNAL OF GLOBAL ONCOLOGY (JGO) IS AN ONLINE ONLY, OPEN ACCESS JOURNAL FOCUSED ON CANCER CARE, RESEARCH AND CARE DELIVERY ISSUES UNIQUE TO COUNTRIES AND SETTINGS WITH LIMITED HEALTHCARE RESOURCES. - JCO CLINICAL CANCER INFORMATICS IS AN ONLINE-ONLY INTERDISCIPLINARY JOURNAL PUBLISHING CLINICALLY RELEVANT RESEARCH BASED ON BIOMEDICAL INFORMATICS METHODS AND PROCESSES APPLIED TO CANCER-RELATED DATA, INFORMATION AND IMAGES. - JCO PRECISION ONCOLOGY IS A PEER-REVIEWED, ONLINE-ONLY, ARTICLE BASED JOURNAL PUBLISHING ORIGINAL RESEARCH, REPORTS, OPINIONS AND REVIEWS THAT ADVANCE THE SCIENCE AND PRACTICE OF PRECISION ONCOLOGY AND DEFINE GENOMICS-DRIVEN CLINICAL CARE OF PATIENTS WITH CANCER. -ASCO PUBLISHES THE ANNUAL CLINICAL CANCER ADVANCES (CCA) REPORT. THIS PUBLICLY-AVAILABLE REPORT ESTABLISHES THE MOST IMPORTANT CLINICAL ADVANCES IN ONCOLOGY EACH YEAR. THE REPORT SERVES TO DOCUMENT THE PROGRESS BEING MADE AGAINST CANCER THROUGH CLINICAL RESEARCH, PARTICULARLY THROUGH FEDERALLY FUNDED RESEARCH. ASCO IS INVOLVED IN THE PRODUCTION OF THE ASCO POST, A TRADE PUBICATION. WHILE NOT OWNED OR PUBLISHED BY ASCO, THIS TRADE COVERS NEWS AND INFORMATION OF INTEREST TO THE PROFESSIONAL ONCOLOGY COMMUNITY AND ASCO PROVIDES ASCO-SPECIFIC CONTENT FOR INCLUSION. FORM 990, PART III, LINE 4D CANCER POLICY AND ADVOCACY: ASCOS POLICY AND ADVOCACY WORK FOCUSES ON THE ISSUES OF ACCESS TO AND DELIVERY OF HIGH-QUALITY CANCER CARE FOR CANCER PATIENTS. WORKING WITH VOLUNTEER ASCO MEMBERS, THE SOCIETY ENGAGES WITH THE ADMINISTRATION, CONGRESS, AND STATE LAW MAKERS TO ADDRESSES POLICY ISSUES OF CRITICAL IMPORTANCE TO THE PRACTICE OF ONCOLOGY AND PATIENT CARE. ASCO'S POLICY AND ADVOCACY PROGRAMS COVER A BROAD SPECTRUM OF ISSUES, INCLUDING CLINICAL CANCER RESEARCH, HEALTH INSURANCE, CLINICAL PRACTICE, WORKFORCE, DISPARITIES, COST/ACCESS, CANCER SURVIVORSHIP, AND CANCER PREVENTION AND CONTROL. ASCO PROVIDES EDUCATIONAL WORKSHOPS AND MATERIALS, LEGAL ANALYSIS, DEVELOPMENT OF FORMAL COMMENTS AND TESTIMONY, ADVOCACY, HOTLINES, TOOLS, AND SPECIAL STUDIES ON CRITICAL ISSUES FOR THE CANCER COMMUNITY. ASCO ROUTINLEY COLLABORATES WITH OTHERS IN THE COMMUNITY TO ADVANCE COMMON GOALS RELATED TO ACCESS TO AND DELIVERY OF HIGH-QUALITY CANCER CARE. - STATE/REGIONAL AFFILIATE PROGRAM. THE 48 STATE/REGIONAL AFFILIATES INTERACT WITH ASCO THROUGH THE STATE AFFILIATE COUNCIL, WHERE EACH SOCIETY HAS A VOTING REPRESENTATIVE CHARGED WITH SERVING AS THE BRIDGE BETWEEN THE SOCIETY AND ASCO. AFFILIATES HAVE ACCESS TO A NUMBER OF PROGRAMS INCLUDING STATE SOCIETY MEMBERSHIP RECRUITMENT AND RETENTION ASSISTANCE, LEADERSHIP TRAINING, FEDERAL-LEVEL ADVOCACY SUPPORT, EDUCATION AND RESOURCES ON PRACTICE-RELATED ISSUES, AND A WEBSITE DEVELOPMENT TOOL. ORIGINAL DATA COLLECTION. ASCO CONDUCTS STUDIES AND ANALYSES TO ASSESS THE CURRENT STATE OF ONCOLOGY CARE AND RESEARCH AND DETERMINE THE NEED FOR AND IMPACT OF POLICY CHANGES. EXPENSES $11,277,636. INCLUDING GRANTS OF $0. REVENUE $89,243. MEMBER SERVICES: ASCO WORKS TO SUPPORT AND EDUCATE ITS MORE THAN 44,000 MEMBERS THROUGH ITS DAILY ACTIVITIES, INCLUDING PROCESSING NEW MEMBERSHIP APPLICATIONS AND MEMBER DUES, PHONE AND EMAIL COMMUNICATIONS, RESEARCHING AND FULFILLING MEMBER REQUESTS, MAINTAINING THE INTEGRITY OF MEMBER DATA, AND NEW MEMBER RECRUITMENT AND RETENTION EFFORTS. ASCO CONNECTION IS THE OFFICIAL MEMBER MAGAZINE FOR AND ABOUT MEMBERS OF ASCO AND THE PRIMARY SOURCE OF INFORMATION ABOUT ASCO'S PROGRAMS AND SERVICES. ALONG WITH ITS COMPANION PROFESSIONAL NETWORKING SITE, ASCOCONNECTION.ORG, ASCO CONNECTION PROMOTES OPPORTUNITIES FOR INTERACTION BETWEEN ASCO AND ITS MEMBERS, AND MEMBERS AND THEIR COLLEAGUES TO FACILITATE THE DISSEMINATION OF INFORMATION RELATING TO CLINICAL RESEARCH, BEST PRACTICES STANDARDS, AND TREATMENT OF PATIENTS. ASCOCONNECTION.ORG FEATURES COMMENTARY BY LEADERS IN THE FIELD, DISCUSSION FORUMS, ONLINE EXCLUSIVES AND COMMENT-ENABLED ARTICLES FROM THE MEMBER MAGAZINE, AS WELL AS OPPORTUNITIES TO CREATE GROUPS. EXPENSES $8,988,354. INCLUDING GRANTS OF $690,327. REVENUE $7,373,722. RESEARCH: ASCO IS ACTIVELY ENGAGED IN THE SUPPORT, PROMOTION AND CONDUCT OF CLINICAL CANCER RESEARCH. RESEARCH RELATED ACTIVITIES INCLUDE: - RESEARCH COMMUNITY FORUM (RCF). ASCO PROVIDES A NETWORK (ONLINE AND IN-PERSON) FOR ALL MEMBERS OF THE ONCOLOGY RESEARCH COMMUNITY TO PROMOTE BEST PRACTICES FOR CONDUCTING AND MANAGING CLINICAL RESEARCH. - ORIGINAL RESEARCH. ASCO CONDUCTS RESEARCH TO DEVELOP EVIDENCE THAT INFORMS PATIENT CARE, PUBLIC POLICY, AND EDUCATION. RESEARCH INCLUDES SURVEYS, OBSERVATIONAL STUDIES AND CLINICAL TRIALS. o TAPUR. ASCO IS CONDUCTING A CLINICAL TRIAL TO TEST THE SAFETY AND EFFICACY OF FDA-APPROVED, TARGETED ANTICANCER DRUGS IN OTHER CANCER TYPES FOR PATIENTS WITH THE SAME GENOMIC ALTERATION. -SCIENTIFIC/RESEARCH COLLABORATIONS. ASCO WORKS WITH OTHER STAKEHOLDERS IN THE COMMUNITY, INCLUDING GOVERNMENT AGENCIES, PATIENT ADVOCACY GROUPS, AND OTHER PROFESSIONAL MEDICAL SOCIETIES TO SUPPORT AND PROMOTE RESEARCH THAT INFORMS EVIDENCE-BASED PATIENT CARE. o ASCO-FDA SCIENTIFIC COLLABORATIONS. ASCO JOINTLY HOSTS PUBLIC WORKSHOPS WITH THE FDA TO PROVIDE STAKEHOLDERS AN OPPORTUNITY TO DISCUSS EMERGING ISSUES IN RESEARCH AND FDA REVIEW OF NEW THERAPIES. - DATA/RESEARCH REQUESTS. ASCO REVIEWS 3RD PARTY REQUESTS TO CONDUCT RESEARCH USING THE SOCIETYS PROPRIETARY ASSETS. EXPENSES $8,655,038. INCLUDING GRANTS OF $0. REVENUE $5,936,693. PATIENT INFORMATION & OTHER: ASCO PROVIDES IMPORTANT INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, RESEARCH, AND PREVENTION FREE OF CHARGE TO THE PUBLIC. ASCOS PATIENT EDUCATION WEBSITE, CANCER.NET (WWW.CANCER.NET) IS PUBLICLY AVAILABLE AND PROVIDES RELIABLE CANCER INFORMATION FROM A TRUSTED SOURCE TO ASCO MEMEBERS, THEIR PATIENTS, CAREGIVERS, FAMILY MEMBERS AND OTHERS. THE SITE PROVIDES ACCURATE, ONCOLOGIST-APPROVED INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, SURVIVORSHIP, RESEARCH, PREVENTION, AND OTHER IMPORTANT TOPICS. THE SITE FEATURES MEDICAL INFORMATION ON MORE THAN 120 TYPES OF CANCER AND RELATED SYNDROMES. IN ADDITION, INFORMATION ON CLINICAL TRIALS, MANAGING SIDE EFFECTS, CAREGIVING, AND HOW TO COPE WITH THE EMOTIONAL AND SOCIAL EFFECTS OF LIVING WITH CANCER CAN BE FOUND ON THE SITE. ASCO ALSO OFFERS PRINTED MATERIALS FOR PATIENTS INCLUDING: - CANCER.NET'S GUIDES TO CANCER. THESE DETAILED GUIDES COVER SYMPTOMS, RISK FACTORS, DIAGNOSIS, STAGING, TREATMENT, CLINICAL TRIAL RESOURCES, SIDE EFFECTS, AFTER TREATMENT, CURRENT RESEARCH AND QUESTIONS TO ASK THE DOCTOR, - ASCO ANSWERS FACT SHEETS. FACT SHEETS PROVIDE AN INTRODUCTION TO A SPECIFIC TYPE OF CANCER OR CANCER-RELATED TOPIC, INCLUDING AN OVERVIEW, AN ILLUSTRATION OF WHERE IT STARTS, HOW IT IS TREATED, TERMS TO KNOW, AND QUESTIONS TO ASK THE DOCTOR. INFORMATIONAL BOOKLETS. BOOKLETS ARE AVAILABLE ON POPULAR TOPICS OF INTEREST: TOBACCO CESSATION, CANCER SURVIVORSHIP, ADVANCED CANCER CARE PLANNING, MANAGING THE COST OF CANCER CARE, AND CANCER IN OLDER ADULTS. EXPENSES $6,599,547. INCLUDING GRANTS OF $0. REVENUE $210,931. FORM 990, PART VI, SECTION A, LINE 1 AS OF DECEMBER 31, 2018, THE BOARD OF DIRECTORS OF ASCO INCLUDED 18 MEMBERS WITH THE RIGHT TO VOTE ON ALL MATTERS THAT COME BEFORE THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES TWO EX-OFFICIO DIRECTORS WITHOUT THE RIGHT TO VOTE, WHO ARE THE CHIEF EXECUTIVE OFFICER OF ASCO (CEO) AND THE CHAIR OF THE BOARD OF DIRECTORS OF CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (A NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION OF ASCO). DURING THE REPORTING YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO ACT ON ITS BEHALF TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. THE VOTING MEMBERS OF THE EXECUTIVE COMMITTEE WERE: THE PRESIDENT, PRESIDENT-ELECT, THE CHAIR, THE PAST PRESIDENT, AND THOSE DIRECTORS SERVING THE FINAL YEAR OF THEIR PRESENT TERMS. THE CEO IS A NON-VOTING MEMBER OF THE EXECUTIVE COMMITTEE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF ASCO'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY ASCO'S BYLAWS, WHICH PROVIDE THAT, EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT MAJOR DECISIONS BETWEEN BOARD MEETINGS AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED BOARD OF DIRECTORS. ALL ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE NEXT MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH ASCO'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 6 ASCO MEMBERS ARE ELECTED BY THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. NO MEMBER IS ENTITLED TO RECEIVE A SHARE OF ASCO'S PROFITS OR EXCESS DUES OR A SHARE OF ASCO'S NET ASSETS UPON DISSOLUTION. THE CATEGORIES OF MEMBERSHIP WITH VOTING RIGHTS AND SPECIFIED RIGHTS ARE AS FOLLOWS: 1. FULL MEMBERS. a. 1.A. FULL MEMBERS ARE (A) EXPERIENCED LICENSED PHYSICIANS OF ANY NATION WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER (IN EXCEPTIONAL CASES, OTHER PHYSICIANS WHO HAVE MADE SIGNIFICANT CONTRIBUTIONS TO THE FIELD ARE ELIGIBLE FOR FULL MEMBER STATUS), AND (B) OTHER HEALTH PROFESSIONALS AT THE DOCTORAL LEVEL (E.G.,EPIDEMIOLOGISTS, BIOSTATISTICIANS, PUBLIC HEALTH SPECIALISTS, NURSES, OTHER SCIENTISTS, ETC.) OR INDIVIDUALS WITH EQUIVALENT ACADEMIC RANKS WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER. b.1.B. RIGHTS OF FULL MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 2. EMERITUS MEMBERS. a.2.A. EMERITUS MEMBERS ARE FULL, ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING AND AFFILIATED HEALTH PROFESSIONAL MEMBERS WHO HAVE REQUESTED EMERITUS STATUS AT AGE 70, UPON RETIREMENT OR EARLIER IF PERMANENTLY DISABLED. b.2.B. EMERITUS MEMBERS WHO AT THE TIME OF THE REQUEST WERE FULL MEMBERS RETAIN THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 3. HONORARY MEMBERS. a.3.A. HONORARY MEMBERS ARE INDIVIDUALS WHO HAVE MADE AN OUTSTANDING CONTRIBUTION TO CLINICAL ONCOLOGY WHO ARE DESIGNATED AS AN HONORARY MEMBER BY THE BOARD OF DIRECTORS. b.3.B. MEMBERS HAVE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. FORM 990, PART VI, SECTION A, LINE 7A VOTING MEMBERS OF ASCO ELECT ALL 18 VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE FOR THE ELECTION OF MEMBERS OF THE GOVERNING BODY ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION A, LINE 7B ASCO'S CERTIFICATE OF INCORPORATION MAY ONLY BE AMENDED UPON THE VOTE OF THE MEMBERS ENTITLED TO VOTE, AND THE BYLAWS MAY ONLY BE AMENDED AND DISSOLUTION OF THE CORPORATION MAY ONLY BE APPROVED WITH THE APPROVAL OF BOTH THE BOARD OF DIRECTORS AND VOTING MEMBERS OF ASCO. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. FORM 990, PART VI, SECTION A, LINE 9 UNFORTUNATELY, ASCO BOARD MEMBER DR. ARTI HURRIA PASSED AWAY IN 2018, AND THEREFORE CANNOT BE REACHED AT THE ORGANIZATION'S MAILING ADDRESS. FORM 990, PART VI, SECTION B, LINE 11 AN ELECTRONIC COPY OF THE ASCO FORM 990 WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS AND WAS DISCUSSED AT A MEETING OF THE BOARD BEFORE IT WAS FILED. THE ASCO FORM 990 WAS REVIEWED BY THE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, THE CHIEF EXECUTIVE OFFICER, AND THE SENIOR VICE PRESIDENT AND CHIEF LEGAL OFFICER PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C ASCO MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL ASCO MEMBERS AND EMPLOYEES, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G. SPOUSE, DEPENDENT CHILDREN). COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS, CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE ALSO REQUIRED TO DISCLOSE SERVICE AS AN OFFICER, DIRECTOR, OR TRUSTEE OF ANY OTHER PROFESSIONAL OR ADVOCACY ORGANIZATION RELATING TO SCIENCE OR HEALTH CARE. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE AND UPDATED ANNUALLY THEREAFTER OR WHEN ANY MATERIAL CHANGES OCCUR. ASCO'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, IF ASCO WERE TO CONTEMPLATE ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY INTERESTED PERSON (I.E. AN ASCO DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF AN ASCO COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 ALL COMPARABILITY DATA DESCRIBED IN THIS STATEMENT INCLUDES DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS. COMPENSATION OF CHIEF EXECUTIVE OFFICER (CEO): THE DUTIES OF THE CEO OF ASCO INCLUDE SERVING AS: THE CEO OF ASCO, THE CEO OF ASCO'S NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CC); THE PRESIDENT OF ASCO'S DISREGARDED LIMITED LIABLITY COMPANY, QOPI CERTIFICATION PROGRAM, LLC (QCP); THE PRESIDENT OF ASCO LEASING LLC, AND THE CHAIR OF THE BOARD OF DIRECTORS OF ASCO'S DISREGARDED LIMITED LIABILITY COMPANY, CANCERLINQ LLC (CLQ). ALL ORGANIZATIONS LISTED ARE RELATED ORGANIZATIONS OF ASCO. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE CEO AND ASCO ADDRESSES COMPENSATION OF THE CEO. THE COMPENSATION OF THE CEO WAS DETERMINED BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO WAS REASONABLE. THE REVIEW, RECOMMENDATION, AND DETERMINATION OF THE CEO'S COMPENSATION BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2018. SENIOR VICE PRESIDENT & CHIEF LEGAL OFFICER (SVP & CLO): THE COMPENSATION OF THE SVP & CLO WAS DETERMING BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE BOARD COMPENSATION COMMITTEE MADE ITS RECOMMENDATION AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE SVP AND CLO WAS REASONABLE. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE SVP & CLO AND ASCO ADDRESS COMPENSATION OF THE SVP & CLO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE SVP & CLO BASED ON THE ABOVE DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2018. VICE PRESIDENT AND CHIEF FINANCIAL OFFICER (VP & CFO): THE COMPENSATION OF THE VP & CFO WAS CONSIDERED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA AND PROVIDED ITS OPINION THAT THE PROPOSED COMPENSATION FOR THE VP & CFO WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE VP & CFO BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2018. SENIOR VICE PRESIDENT & CHIEF MEDICAL OFFICER (SVP & CMO): THE COMPENSATION OF THE SVP & CMO WAS CONSIDERED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE SVP & CMO WAS REASONABLE. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE SVP & CMO AND ASCO ADDRESS COMPENSATION OF THE SVP & CMO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE SVP & CMO BASED ON THE ABOVE DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2018. EXECUTIVE VICE PRESIDENT & CHIEF PHILANTHROPIC OFFICER (EVP & CPO) OF THE CONQUER CANCER FOUNDATION OF THE AMERICA SOCIETY OF CLINICAL ONCOLOGY (CC): THE EVP & CPO OF CC IS AN EMPLOYEE OF ASCO. THE ASCO BOARD COMPENSATION COMMITTEE CONSIDERED THE COMPENSATION OF THE EVP & CPO OF CC AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE EXECUTIVE VICE PRESIDENT & CHIEF PHILANTHROPIC OFFICER OF CC WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CPO OF CC BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2018. CHIEF EXECUTIVE OFFICER OF CANCERLINQ LLC (CLQ): THE CEO OF CLQ IS AN EMPLOYEE OF ASCO. THE COMPENSATION OF THE CEO OF CLQ WAS CONSIDERED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE ASCO CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO OF CLQ WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE SVP & CMO BASED ON THE ABOVE DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2018. VICE PRESIDENT, INTEGRATED MEDIA AND TECHNOLOGY (VP IMT): THE COMPENSATION OF THE VP IMT WAS CONSIDERED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE VICE PRESIDENT, INTEGRATED MEDIA AND TECHNOLOGY WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE VP IMT BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2018. FORM 990, PART VI, SECTION C, LINE 19 ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S ANNUAL REPORT IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. FORM 990, PART XI, LINE 9 GAIN ON INTEREST RATE SWAP $2,587,908 FORM 990 PART IX LINE 11G DESCRIPTION:COMMISSIONS TOTAL FEES:5488652 FORM 990 PART IX LINE 11G DESCRIPTION:PUBLIC RELATIONS COORDINATOR TOTAL FEES:1183936 FORM 990 PART IX LINE 11G DESCRIPTION:OTHER PROFESSIONAL SERVICES TOTAL FEES:21503925 QOPI Certification Program LLC 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 271629211 accreditation VA 625980 1008436 ASCO ASCO LEASING LLC 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 273378225 RENTAL VA 213178 108254 ASCO CANCERLINQ LLC 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 472315885 QUALITY IMprv VA 24799146 9287254 ASCO CONQUER CANCER FOUNDATION OF ASCO 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 311667995 Grants VA 501(C)(3) 7 asco true true true true false true false false false false true false false true true true true true false false conquer cancer foundation of asco b 3503004 fmv conquer cancer foundation of asco c 8429775 fmv conquer cancer foundation of asco e 57070000 fmv conquer cancer foundation of asco A, j 461146 fmv conquer cancer foundation of asco m 3050004 fmv conquer cancer foundation of asco n 461146 fmv